【Youth Daily】 Daewon Pharmaceutical and Boryeong Pharmaceutical announced on the 24th that they have signed a joint promotion contract for two types of’Kanab Family’, a new drug for treating hypertension.
At the signing ceremony of the joint promotion contract held at the headquarters of Daewon Pharmaceutical, Daewon Pharmaceutical Vice Chairman Seung-Yeol Baek, President Tae-Hong Choi, and CEO Ahn Jae-Hyun and Lee Sam-Soo of Boryeong Pharmaceutical attended.
The two products that will be jointly sold are’Akab’ and’Tubero’, a combination drug of’Kannab’, an existing high blood pressure treatment, plus a treatment for hyperlipidemia, among Boryeong Pharmaceutical’s representative blockbuster new drug’Kannab’ family.
‘Tubero’ is a product that improves the patient’s medication convenience by combining’Pimasartan’, an ingredient of Kanab, a new hypertension drug, and’Rosuvastatin’, a treatment ingredient for hyperlipidemia, and was launched in 2016.’Akab’ is Kanab’s It is a new product released this year as a combination of the ingredient’pimasartan’ and’atorvastatin’, which is used as a treatment for hyperlipidemia.
Since many hypertensive patients have hyperlipidemia, the proportion of combination drugs in the hypertension treatment market is constantly increasing.
With this contract, the distribution, sales and marketing of’Tubero’ to all domestic hospitals and clinics will be handled by Daewon Pharmaceutical, and the distribution of’Akave’ will be conducted by Daewon Pharmaceutical, and sales and marketing will be jointly conducted by both companies.
Jae-Hyun Ahn, CEO of Boryeong Pharmaceutical said, “The Kanab Family is recognized for its marketability at home and abroad through its excellent clinical value as a successful model for domestic new drugs. Through this cooperation, it goes beyond becoming another success model for collaboration between domestic companies. We look forward to helping more patients improve their quality of life.”
Daewon Pharm’s Vice Chairman Seung-Yeol Baek said, “Based on Daewon Pharmaceutical’s differentiated marketing capabilities and sales know-how, we are striving to expand the market share of the’Kannab’ brand so that more hypertension and hyperlipidemia patients can benefit from the treatment benefits of the innovative new drug Kanab family “We will continue to expand our product portfolio in the area of chronic diseases in the future so that we can contribute to improving the health of the people.”
【Youth Daily = Reporter Ahn Sang-jun】
Meanwhile, according to the drug research institute UBIST, the domestic hypertension/hyperlipidemia combination market is estimated to be about KRW 114.3 billion by the third quarter of this year. The’Kannab’ family recorded a cumulative prescription amount of 94.3 billion won until November of this year, which is a strong breakthrough of 100 billion won this year.